Status:
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Lead Sponsor:
AstraZeneca
Conditions:
Non-squamous Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatmen...
Detailed Description
This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based ...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
November 27 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 25 2030
Estimated Enrollment :
878 Patients enrolled
Trial Details
Trial ID
NCT06627647
Start Date
November 27 2024
End Date
March 25 2030
Last Update
February 12 2026
Active Locations (282)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Mobile, Alabama, United States, 36608
2
Research Site
Chandler, Arizona, United States, 85224
3
Research Site
Phoenix, Arizona, United States, 85054
4
Research Site
Anaheim, California, United States, 92801